Genmab | GEN - Gewinn Vor Steuern

Aktienkurs
1,637.00
Täglich Wechseln
-8.00 -0.49%
Monatlich
-10.67%
Jährlich
20.06%
Q1 Prognose
1,614.31




Gewinn Vor Steuern Veränderung Datum
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Almirall EUR 30.32M 22M 2025-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 3.92B 2.35B 2025-09
argenx SE USD 386.05M 99.15M 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Bayer EUR -1.16B 735M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Demant DKK 1.46B 497M 2025-06
Exelixis USD 252.69M 275K 2025-12
Fresenius Medical Care EUR 508.46M 105.89M 2025-12
Galapagos EUR -221.49M 117.07M 2025-09
Genmab DKK 55M 427M 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
GN Store Nord DKK 450M 332M 2025-12
GRIFOLS EUR 190.51M 20.03M 2025-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
Insmed USD -326.93M 41.77M 2025-12
Lonza CHF 624M 197M 2024-12
Merck EUR 1.29B 458.1M 2025-09
Novartis USD 4.64B 445M 2025-12
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
UCB EUR 789M 427M 2025-06